Nicholas A. Smith

Array ( [id] => 4982447 [patent_doc_number] => 20070087005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-04-19 [patent_title] => 'Anti-glypican-3 antibody' [patent_app_type] => utility [patent_app_number] => 11/251561 [patent_app_country] => US [patent_app_date] => 2005-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9815 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0087/20070087005.pdf [firstpage_image] =>[orig_patent_app_number] => 11251561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5045584 [patent_doc_number] => 20070264257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-15 [patent_title] => 'Immunotherapy of autoimmune disorders' [patent_app_type] => utility [patent_app_number] => 11/246541 [patent_app_country] => US [patent_app_date] => 2005-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 35672 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0264/20070264257.pdf [firstpage_image] =>[orig_patent_app_number] => 11246541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4791659 [patent_doc_number] => 20080292632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-11-27 [patent_title] => 'Irta2 Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 11/664211 [patent_app_country] => US [patent_app_date] => 2005-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 29456 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0292/20080292632.pdf [firstpage_image] =>[orig_patent_app_number] => 11664211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4663055 [patent_doc_number] => 20080253962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-16 [patent_title] => 'Irta-4 Antibodies and Their Uses' [patent_app_type] => utility [patent_app_number] => 11/664193 [patent_app_country] => US [patent_app_date] => 2005-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 27135 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0253/20080253962.pdf [firstpage_image] =>[orig_patent_app_number] => 11664193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5721449 [patent_doc_number] => 20060074225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-04-06 [patent_title] => 'Monomeric immunoglobulin Fc domains' [patent_app_type] => utility [patent_app_number] => 11/228026 [patent_app_country] => US [patent_app_date] => 2005-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 29066 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20060074225.pdf [firstpage_image] =>[orig_patent_app_number] => 11228026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5720368 [patent_doc_number] => 20060073142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-04-06 [patent_title] => 'Anti-Fc-gamma RIIB receptor antibody and uses therefor' [patent_app_type] => utility [patent_app_number] => 11/217995 [patent_app_country] => US [patent_app_date] => 2005-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 39279 [patent_no_of_claims] => 86 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0073/20060073142.pdf [firstpage_image] =>[orig_patent_app_number] => 11217995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5636957 [patent_doc_number] => 20060067930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-03-30 [patent_title] => 'Polypeptide variants with altered effector function' [patent_app_type] => utility [patent_app_number] => 11/208422 [patent_app_country] => US [patent_app_date] => 2005-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13768 [patent_no_of_claims] => 80 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0067/20060067930.pdf [firstpage_image] =>[orig_patent_app_number] => 11208422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5590453 [patent_doc_number] => 20060039904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-23 [patent_title] => 'EPH receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity' [patent_app_type] => utility [patent_app_number] => 11/203251 [patent_app_country] => US [patent_app_date] => 2005-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 55693 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20060039904.pdf [firstpage_image] =>[orig_patent_app_number] => 11203251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5590451 [patent_doc_number] => 20060039902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-23 [patent_title] => 'Antagonizing interleukin-21 receptor activity' [patent_app_type] => utility [patent_app_number] => 11/197488 [patent_app_country] => US [patent_app_date] => 2005-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 64 [patent_no_of_words] => 32199 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20060039902.pdf [firstpage_image] =>[orig_patent_app_number] => 11197488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5799287 [patent_doc_number] => 20060034828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-16 [patent_title] => 'Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187066 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19923 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20060034828.pdf [firstpage_image] =>[orig_patent_app_number] => 11187066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5819991 [patent_doc_number] => 20060024304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-02 [patent_title] => 'Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187196 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20577 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0024/20060024304.pdf [firstpage_image] =>[orig_patent_app_number] => 11187196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5799288 [patent_doc_number] => 20060034829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-16 [patent_title] => 'Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187079 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19925 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20060034829.pdf [firstpage_image] =>[orig_patent_app_number] => 11187079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5880522 [patent_doc_number] => 20060029604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-09 [patent_title] => 'Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187229 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19512 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0029/20060029604.pdf [firstpage_image] =>[orig_patent_app_number] => 11187229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5819979 [patent_doc_number] => 20060024292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-02 [patent_title] => 'Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187065 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19418 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0024/20060024292.pdf [firstpage_image] =>[orig_patent_app_number] => 11187065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5799289 [patent_doc_number] => 20060034830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-16 [patent_title] => 'Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform' [patent_app_type] => utility [patent_app_number] => 11/187113 [patent_app_country] => US [patent_app_date] => 2005-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20033 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20060034830.pdf [firstpage_image] =>[orig_patent_app_number] => 11187113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6930789 [patent_doc_number] => 20050281823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-12-22 [patent_title] => 'Antibodies against human IL-12' [patent_app_type] => utility [patent_app_number] => 11/185615 [patent_app_country] => US [patent_app_date] => 2005-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10600 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0281/20050281823.pdf [firstpage_image] =>[orig_patent_app_number] => 11185615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5767607 [patent_doc_number] => 20060019294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-01-26 [patent_title] => 'Tyrosine kinase substrate (Tks) proteins' [patent_app_type] => utility [patent_app_number] => 11/182016 [patent_app_country] => US [patent_app_date] => 2005-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 25520 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0019/20060019294.pdf [firstpage_image] =>[orig_patent_app_number] => 11182016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5590920 [patent_doc_number] => 20060040372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-02-23 [patent_title] => 'GANP protein' [patent_app_type] => utility [patent_app_number] => 11/179624 [patent_app_country] => US [patent_app_date] => 2005-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 10907 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20060040372.pdf [firstpage_image] =>[orig_patent_app_number] => 11179624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7597760 [patent_doc_number] => 07618817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-11-17 [patent_title] => 'Genetically modified human natural killer cell lines' [patent_app_type] => utility [patent_app_number] => 11/178258 [patent_app_country] => US [patent_app_date] => 2005-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 24164 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/618/07618817.pdf [firstpage_image] =>[orig_patent_app_number] => 11178258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5842223 [patent_doc_number] => 20060121032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-06-08 [patent_title] => 'Optimized anti-CD20 monoclonal antibodies having Fc variants' [patent_app_type] => utility [patent_app_number] => 11/174287 [patent_app_country] => US [patent_app_date] => 2005-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 52771 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20060121032.pdf [firstpage_image] =>[orig_patent_app_number] => 11174287 [rel_patent_id] =>[rel_patent_doc_number] =>)